Pharmos/Pharmatec merger
Executive Summary
President and COO of the combined companies will be Pharmos co- Chairman Stephen Streber, who joins Pharmos from biotech start-up Innovir where he was president and CEO. Prior to Innovir, Streber was president of Roussel-Uclaf's U.S. operations. In addition, Henry Dachowitz joins the soon-to-be merged companies from Richard A. Eisner & Co. as chief financial officer. A definitive merger agreement was announced by Israeli firm Pharmos and Gainesville, Fla.-based Pharmatec in May as well as an option to acquire Xenon Vision ("The Pink Sheet" May 18, T&G-10).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth